Genentech / Astex | Breast Cancer Discovery Collaboration Amid gRED Restructuring

Summary Genentech entered a breast cancer drug discovery collaboration with Astex Pharmaceuticals worth up to $490 million in milestones, while Fierce Biotech reported that 103 roles were affected as part of Genentech Research and Early Development changes. This is lower priority for Insilens because it…